Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

Mohit Sodhi; Ramin Rezaeianzadeh; Abbas Kezouh; Mahyar Etminan

doi:10.1001/jama.2023.19574

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

JAMA. 2023 Nov 14;330(18):1795-1797. doi: 10.1001/jama.2023.19574.

Authors

Mohit Sodhi¹, Ramin Rezaeianzadeh¹, Abbas Kezouh², Mahyar Etminan³

Affiliations

¹ Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
² StatExpert Ltd, Laval, Quebec, Canada.
³ Department of Ophthalmology and Visual Sciences and Medicine, University of British Columbia, Vancouver, Canada.

No abstract available

Plain language summary

This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.

MeSH terms

Anti-Obesity Agents* / adverse effects
Anti-Obesity Agents* / pharmacology
Anti-Obesity Agents* / therapeutic use
Diabetes Mellitus, Type 2 / drug therapy
Gastrointestinal Diseases* / chemically induced
Glucagon-Like Peptide-1 Receptor Agonists*
Glucagon-Like Peptides
Humans
Hypoglycemic Agents / adverse effects
Hypoglycemic Agents / therapeutic use
Liraglutide / adverse effects
Liraglutide / therapeutic use
Overweight* / drug therapy
Weight Loss* / drug effects

Substances

Glucagon-Like Peptides
Hypoglycemic Agents
Liraglutide
Anti-Obesity Agents
Glucagon-Like Peptide-1 Receptor Agonists